Hepatitis C virus infection, cryoglobulinaemia, and beyond

被引:68
作者
Sansonno, D.
Carbone, A.
De Re, V.
Dammacco, F.
机构
[1] Univ Bari, Sch Med, Policlin, Dept Internal Med & Clin Oncol, I-70124 Bari, Italy
[2] Ctr Riferimento Oncol, Div Expt Oncol, Aviano, Italy
[3] Ist Nazl Tumori, Dept Pathol, I-20133 Milan, Italy
关键词
D O I
10.1093/rheumatology/kel425
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hepatitis C virus (HCV) infection is the major cause of mixed cryoglobulinaemia (MC), an immune complex (IC)-mediated systemic vasculitis mainly involving the small blood vessels. The precise mechanism of cryoprotein production is currently unknown. HCV virions and non-enveloped core protein participate in the formation of cold-insoluble ICs. Cryoglobulinaemic patients represent a distinct HCV-infected population, in that significant HCV enrichment of lymphoid cells is accompanied by evidence of productive virus infection and increased frequency of B cells. Liver, the major target organ of HCV, is the site of accumulation of inflammatory infiltrates that shares many architectural features with lymphoid tissue and reflects a distorted homeostatic balance between factors that enhance cellular recruitment, proliferation and retention, and those that decrease cellularity (cell death and emigration). There is now overwhelming evidence of a direct contribution to B-cell growth and survival through production of a variety of cytokines and chemokines. Liver tissue over-expression and abnormal circulating levels of B-cell activating factor belonging to the TNF family can provide effective costimulatory mechanisms to sustain the B-cell clonal expansion, which constitutes molecular stigmata of MC. Indolent lymphoproliferation might act as the starting point of chronic, multistage lymphomagenesis. An innovative therapeutic strategy is directed to 'eradication of the virus' and deletion of B-cell clonalities.
引用
收藏
页码:572 / 578
页数:7
相关论文
共 118 条
  • [71] REAPPRAISAL OF THE CLINICAL EXPRESSION OF MIXED CRYOGLOBULINEMIA
    MONTAGNINO, G
    [J]. SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1988, 10 (01): : 1 - 19
  • [72] MONTI G, 1995, QJM-MON J ASSOC PHYS, V88, P115
  • [73] MUSSET L, 1992, CLIN CHEM, V38, P798
  • [74] Rheumatoid factors: Host resistance or autoimmunity?
    Newkirk, MM
    [J]. CLINICAL IMMUNOLOGY, 2002, 104 (01) : 1 - 13
  • [75] MONOCLONAL RHEUMATOID FACTOR-IGG IMMUNE-COMPLEXES - POOR FIXATION OF OPSONIC C-4 AND C-3 DESPITE EFFICIENT COMPLEMENT ACTIVATION
    NG, YC
    PETERS, DK
    WALPORT, MJ
    [J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (01): : 99 - 107
  • [76] Central nervous system involvement in patients with HCV-related cryoglobulinemia
    Origgi, L
    Vanoli, M
    Carbone, A
    Grasso, M
    Scorza, R
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1998, 315 (03) : 208 - 210
  • [77] Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: Implications of HCV lymphotropism
    Pal, S
    Sullivan, DG
    Kim, S
    Lai, KKY
    Kae, J
    Cotler, SJ
    Carithers, RL
    Wood, BL
    Perkins, JD
    Gretch, DR
    [J]. GASTROENTEROLOGY, 2006, 130 (04) : 1107 - 1116
  • [78] Survival signaling in resting B cells
    Patke, A
    Mecklenbräuker, I
    Tarakhovsky, A
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2004, 16 (02) : 251 - 255
  • [79] PAWLOTSKY JM, 1994, HEPATOLOGY, V19, P841, DOI 10.1002/hep.1840190407
  • [80] Structure-function analysis of hepatitis C virus envelope-CD81 binding
    Petracca, R
    Falugi, F
    Galli, G
    Norais, N
    Rosa, D
    Campagnoli, S
    Burgio, V
    Di Stasio, E
    Giardina, B
    Houghton, M
    Abrignani, S
    Grandi, G
    [J]. JOURNAL OF VIROLOGY, 2000, 74 (10) : 4824 - 4830